ruxolitinib (systemic)
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
rux-oh-li-ti-nib
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Jakafi
- Jakavi
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Ruxolitinib (systemic)." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2026. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/3580032/all/ruxolitinib__systemic_.
Vallerand AHA, Sanoski CAC, . Ruxolitinib (systemic). Davis's Drug Guide. F.A. Davis Company; 2026. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/3580032/all/ruxolitinib__systemic_. Accessed April 27, 2026.
Vallerand, A. H., Sanoski, C. A., & , (2026). Ruxolitinib (systemic). In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/3580032/all/ruxolitinib__systemic_
Vallerand AHA, Sanoski CAC, . Ruxolitinib (systemic) [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 April 27]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/3580032/all/ruxolitinib__systemic_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ruxolitinib (systemic)
ID - 3580032
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/3580032/all/ruxolitinib__systemic_
PB - F.A. Davis Company
ET - 19
DB - The Washington Manual
DP - Unbound Medicine
ER -

Davis's Drug Guide

